Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BYUrology case reports

Peristomal skin and subcutaneous tissue metastasis of urothelial carcinoma and successful treatment with immunotherapy: A 5-year follow-up case report.

  • Fürkan Batuhan Güven1
  • Hasan Soydan1
  • Zeynep Tekdemir1
  • Furkan Bingöloğlu1
  • Ahmet Kenan Karademir1
  1. 1Department of Urology, Faculty of Medicine, Maltepe University, Maltepe, Istanbul, Türkiye.
Read full textPDFDOICite

Abstract

Cutaneous metastasis of urothelial carcinoma is an extremely rare condition following muscle-invasive bladder cancer. Recent studies are highlighting the importance of immunotherapy. A 73-year-old patient presented to our clinic with muscle-invasive bladder cancer. Radical cystectomy was performed with the formation of ileal conduit. Six months after the adjuvant chemotherapy, the patient presented with peristomal skin and deep tissue metastasis. Intravenous immunotherapy (Atezolizumab) was applied for 14 cycles as a second-line treatment after metastasectomy. The patient remains disease-free after 5 years of follow-up without further medical intervention.

Related

  1. Penile metastasis from urothelial carcinoma of the bladder: An exceptionally rare localization
    Yosr Zenzri, Wassim Ammar, Farah Bouali +6
    Urology case reportsPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Circulating and tumor microenvironment immunomarkers associate with immunotherapy efficacy in advanced bladder urothelial carcinoma: an exploratory multicenter study integrating genomic and immunophenotypic profiling
    Sha Liu, Junjun Lu, Zhaojie Lyu +7
    ImmunotherapyPeer-reviewedLicence not statedFull textOncologyPMC
  3. 455 Second primary malignancy risk in the immunotherapy era among urothelial carcinoma survivors: a SEER population-based analysis
    Jeffrey Afrifa-Yamoah, Damilola Ologbe, Duresha Malik +6
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYImmunologyOncologyDOAJ
  4. Incremental Predictive Value and Representation of Transcriptomic Features for Immunotherapy Response in Advanced Urothelial Carcinoma
    G. Y. Han, H. Tai, F. Wang
    medRxivPreprintCC BYFull textOncologymedRxiv
  5. Sarcomatoid urothelial carcinoma of the urethra with an unusual right ventricular metastasis: a case report and review of literature
    Jesús Yaringaño, Javier Calvo-Losada, Gerard Oristrell +8
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textCardiovascular medicineCrossrefPMC

Cite

BibTeXRIS
BibTeX
@article{guven2026peristomal,
  title = {{Peristomal skin and subcutaneous tissue metastasis of urothelial carcinoma and successful treatment with immunotherapy: A 5-year follow-up case report.}},
  author = {Fürkan Batuhan Güven and Hasan Soydan and Zeynep Tekdemir and Furkan Bingöloğlu and Ahmet Kenan Karademir},
  journal = {Urology case reports},
  year = {2026},
  month = oct,
  doi = {10.1016/j.eucr.2026.103642},
  url = {https://europepmc.org/article/MED/42921434},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Peristomal skin and subcutaneous tissue metastasis of urothelial carcinoma and successful treatment with immunotherapy: A 5-year follow-up case report.
AU  - Fürkan Batuhan Güven
AU  - Hasan Soydan
AU  - Zeynep Tekdemir
AU  - Furkan Bingöloğlu
AU  - Ahmet Kenan Karademir
PY  - 2026
DA  - 2026/10/12
JO  - Urology case reports
DO  - 10.1016/j.eucr.2026.103642
UR  - https://europepmc.org/article/MED/42921434
AB  - Cutaneous metastasis of urothelial carcinoma is an extremely rare condition following muscle-invasive bladder cancer. Recent studies are highlighting the importance of immunotherapy. A 73-year-old patient presented to our clinic with muscle-invasive bladder cancer. Radical cystectomy was performed with the formation of ileal conduit. Six months after the adjuvant chemotherapy, the patient presented with peristomal skin and deep tissue metastasis. Intravenous immunotherapy (Atezolizumab) was applied for 14 cycles as a second-line treatment after metastasectomy. The patient remains disease-free after 5 years of follow-up without further medical intervention.
SN  - 2214-4420
ER  -